| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Contrast Media | 31 | 2025 | 473 | 5.630 |
Why?
|
| Nanoparticles | 20 | 2025 | 232 | 3.900 |
Why?
|
| Liposomes | 30 | 2019 | 174 | 2.920 |
Why?
|
| Magnetic Resonance Imaging | 16 | 2025 | 3571 | 2.280 |
Why?
|
| Placenta | 6 | 2025 | 506 | 1.940 |
Why?
|
| Tomography, X-Ray Computed | 15 | 2025 | 2092 | 1.930 |
Why?
|
| Plaque, Atherosclerotic | 3 | 2022 | 122 | 1.580 |
Why?
|
| Drug Carriers | 12 | 2012 | 100 | 1.370 |
Why?
|
| Gadolinium | 7 | 2019 | 106 | 1.350 |
Why?
|
| Optical Imaging | 3 | 2018 | 65 | 1.260 |
Why?
|
| Indocyanine Green | 3 | 2023 | 59 | 1.190 |
Why?
|
| Fluorocarbons | 2 | 2018 | 55 | 1.160 |
Why?
|
| Alzheimer Disease | 6 | 2024 | 798 | 1.130 |
Why?
|
| Computer-Aided Design | 2 | 2020 | 21 | 1.130 |
Why?
|
| Models, Anatomic | 2 | 2020 | 99 | 1.060 |
Why?
|
| Imaging, Three-Dimensional | 4 | 2021 | 370 | 1.050 |
Why?
|
| Drug Delivery Systems | 7 | 2012 | 186 | 1.030 |
Why?
|
| Triiodobenzoic Acids | 5 | 2021 | 29 | 1.020 |
Why?
|
| Ferrosoferric Oxide | 1 | 2025 | 25 | 0.920 |
Why?
|
| Phantoms, Imaging | 4 | 2018 | 134 | 0.850 |
Why?
|
| Animals | 51 | 2025 | 34019 | 0.840 |
Why?
|
| Placenta Accreta | 1 | 2025 | 157 | 0.780 |
Why?
|
| X-Ray Microtomography | 3 | 2021 | 83 | 0.770 |
Why?
|
| Mice | 29 | 2025 | 17573 | 0.760 |
Why?
|
| Plaque, Amyloid | 3 | 2020 | 64 | 0.760 |
Why?
|
| Angiography | 2 | 2021 | 215 | 0.760 |
Why?
|
| Hydrophobic and Hydrophilic Interactions | 2 | 2018 | 57 | 0.730 |
Why?
|
| Cerebrovascular Disorders | 1 | 2021 | 122 | 0.700 |
Why?
|
| Atherosclerosis | 2 | 2022 | 914 | 0.680 |
Why?
|
| Printing, Three-Dimensional | 1 | 2020 | 69 | 0.660 |
Why?
|
| Medical Oncology | 2 | 2023 | 213 | 0.650 |
Why?
|
| Computer Simulation | 2 | 2021 | 646 | 0.640 |
Why?
|
| Insulin | 3 | 2012 | 1201 | 0.630 |
Why?
|
| Fluorine | 1 | 2018 | 15 | 0.620 |
Why?
|
| Disease Models, Animal | 14 | 2022 | 4344 | 0.620 |
Why?
|
| Amyloid | 2 | 2020 | 65 | 0.610 |
Why?
|
| Hindlimb | 1 | 2018 | 76 | 0.600 |
Why?
|
| Integrin alpha4beta1 | 1 | 2018 | 17 | 0.590 |
Why?
|
| Fluorine-19 Magnetic Resonance Imaging | 1 | 2018 | 4 | 0.590 |
Why?
|
| Ethers | 1 | 2018 | 7 | 0.590 |
Why?
|
| Neoplasms | 7 | 2023 | 2790 | 0.590 |
Why?
|
| Radiography, Thoracic | 3 | 2015 | 152 | 0.560 |
Why?
|
| Aortography | 2 | 2021 | 199 | 0.560 |
Why?
|
| Skull | 1 | 2018 | 142 | 0.550 |
Why?
|
| Immunotherapy | 3 | 2023 | 673 | 0.550 |
Why?
|
| Amyloid beta-Protein Precursor | 3 | 2020 | 127 | 0.530 |
Why?
|
| Blood-Brain Barrier | 2 | 2014 | 143 | 0.520 |
Why?
|
| Neuroblastoma | 2 | 2021 | 520 | 0.500 |
Why?
|
| Pulmonary Blastoma | 1 | 2015 | 11 | 0.480 |
Why?
|
| Aorta | 3 | 2021 | 541 | 0.470 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2014 | 13 | 0.460 |
Why?
|
| Ribonuclease III | 1 | 2015 | 89 | 0.460 |
Why?
|
| Mammary Neoplasms, Experimental | 3 | 2011 | 247 | 0.460 |
Why?
|
| Presenilin-1 | 2 | 2020 | 53 | 0.450 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2015 | 121 | 0.450 |
Why?
|
| Lung | 4 | 2007 | 1490 | 0.450 |
Why?
|
| Computer Peripherals | 1 | 2013 | 4 | 0.440 |
Why?
|
| Cerebral Arteries | 1 | 2014 | 80 | 0.440 |
Why?
|
| Stroke | 1 | 2021 | 987 | 0.420 |
Why?
|
| Nanostructures | 4 | 2008 | 51 | 0.420 |
Why?
|
| Vascular Diseases | 1 | 2015 | 168 | 0.410 |
Why?
|
| Musculoskeletal Diseases | 1 | 2013 | 57 | 0.410 |
Why?
|
| Chest Pain | 1 | 2013 | 126 | 0.400 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2013 | 217 | 0.390 |
Why?
|
| Nanomedicine | 1 | 2012 | 14 | 0.390 |
Why?
|
| Cerebrovascular Circulation | 1 | 2015 | 432 | 0.380 |
Why?
|
| Mice, Knockout | 4 | 2025 | 3716 | 0.380 |
Why?
|
| Delayed-Action Preparations | 3 | 2007 | 110 | 0.380 |
Why?
|
| Boronic Acids | 1 | 2012 | 47 | 0.380 |
Why?
|
| Diagnostic Imaging | 2 | 2015 | 276 | 0.370 |
Why?
|
| Coronary Angiography | 1 | 2013 | 441 | 0.360 |
Why?
|
| Amyloid beta-Peptides | 1 | 2012 | 211 | 0.360 |
Why?
|
| Pediatrics | 1 | 2020 | 1166 | 0.360 |
Why?
|
| Mice, Transgenic | 6 | 2022 | 2384 | 0.350 |
Why?
|
| Neuroimaging | 3 | 2021 | 340 | 0.350 |
Why?
|
| Humans | 42 | 2025 | 124790 | 0.350 |
Why?
|
| Aortic Diseases | 1 | 2013 | 199 | 0.350 |
Why?
|
| Health Care Costs | 1 | 2013 | 371 | 0.350 |
Why?
|
| Tumor Microenvironment | 3 | 2021 | 557 | 0.340 |
Why?
|
| Models, Biological | 4 | 2011 | 1458 | 0.340 |
Why?
|
| Rats | 13 | 2020 | 3674 | 0.340 |
Why?
|
| Lung Neoplasms | 3 | 2015 | 1659 | 0.330 |
Why?
|
| Brain | 4 | 2024 | 2987 | 0.330 |
Why?
|
| Polyethylene Glycols | 6 | 2012 | 225 | 0.320 |
Why?
|
| Female | 23 | 2025 | 66593 | 0.300 |
Why?
|
| Particle Size | 6 | 2009 | 122 | 0.290 |
Why?
|
| Administration, Inhalation | 5 | 2007 | 180 | 0.280 |
Why?
|
| Iohexol | 2 | 2007 | 21 | 0.280 |
Why?
|
| Aerosols | 2 | 2007 | 65 | 0.270 |
Why?
|
| Pregnancy | 6 | 2025 | 7171 | 0.270 |
Why?
|
| Systemic Inflammatory Response Syndrome | 3 | 2022 | 175 | 0.260 |
Why?
|
| Ciprofloxacin | 1 | 2007 | 66 | 0.260 |
Why?
|
| Glucose | 2 | 2012 | 875 | 0.260 |
Why?
|
| Mice, Nude | 4 | 2018 | 707 | 0.260 |
Why?
|
| Cardiology | 1 | 2012 | 504 | 0.260 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2017 | 1230 | 0.260 |
Why?
|
| Emergency Service, Hospital | 1 | 2013 | 1088 | 0.250 |
Why?
|
| Receptors, Cell Surface | 2 | 2005 | 469 | 0.250 |
Why?
|
| Ligands | 4 | 2021 | 532 | 0.240 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2015 | 3153 | 0.230 |
Why?
|
| Microspheres | 1 | 2003 | 70 | 0.220 |
Why?
|
| Child | 12 | 2023 | 24410 | 0.220 |
Why?
|
| Tumor Burden | 4 | 2021 | 230 | 0.220 |
Why?
|
| Folic Acid | 2 | 2006 | 293 | 0.220 |
Why?
|
| Mouth Neoplasms | 2 | 2023 | 84 | 0.220 |
Why?
|
| Image Processing, Computer-Assisted | 5 | 2019 | 580 | 0.210 |
Why?
|
| Tomography, Spiral Computed | 1 | 2003 | 16 | 0.210 |
Why?
|
| Rheology | 1 | 2003 | 32 | 0.210 |
Why?
|
| Carrier Proteins | 2 | 2005 | 1022 | 0.200 |
Why?
|
| Bronchi | 1 | 2003 | 98 | 0.200 |
Why?
|
| Antineoplastic Agents | 5 | 2011 | 1662 | 0.200 |
Why?
|
| Vimentin | 1 | 2022 | 66 | 0.200 |
Why?
|
| Adventitia | 1 | 2022 | 6 | 0.190 |
Why?
|
| Image Enhancement | 3 | 2008 | 163 | 0.190 |
Why?
|
| Protein Binding | 2 | 2018 | 1735 | 0.190 |
Why?
|
| Trachea | 1 | 2003 | 202 | 0.180 |
Why?
|
| Indans | 1 | 2021 | 55 | 0.180 |
Why?
|
| Mice, Inbred C57BL | 4 | 2021 | 4366 | 0.180 |
Why?
|
| Biomarkers, Tumor | 1 | 2009 | 1486 | 0.180 |
Why?
|
| Spectroscopy, Near-Infrared | 2 | 2023 | 136 | 0.180 |
Why?
|
| Male | 17 | 2022 | 61300 | 0.180 |
Why?
|
| Moyamoya Disease | 1 | 2021 | 38 | 0.180 |
Why?
|
| Regional Blood Flow | 1 | 2021 | 207 | 0.180 |
Why?
|
| Disposable Equipment | 1 | 2020 | 17 | 0.180 |
Why?
|
| Structure-Activity Relationship | 2 | 2021 | 574 | 0.180 |
Why?
|
| Cell Line, Tumor | 7 | 2016 | 3335 | 0.170 |
Why?
|
| alpha-Synuclein | 1 | 2021 | 122 | 0.170 |
Why?
|
| Cognitive Dysfunction | 1 | 2024 | 238 | 0.170 |
Why?
|
| Nanotechnology | 3 | 2009 | 49 | 0.170 |
Why?
|
| Nasopharynx | 1 | 2020 | 79 | 0.170 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2021 | 95 | 0.170 |
Why?
|
| Appendicitis | 1 | 2021 | 126 | 0.170 |
Why?
|
| Finger Phalanges | 1 | 2019 | 3 | 0.170 |
Why?
|
| Age Determination by Skeleton | 1 | 2019 | 9 | 0.170 |
Why?
|
| Neuroprotective Agents | 1 | 2021 | 158 | 0.170 |
Why?
|
| tau Proteins | 1 | 2022 | 206 | 0.170 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2020 | 47 | 0.170 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 2153 | 0.160 |
Why?
|
| Aortic Rupture | 1 | 2021 | 120 | 0.160 |
Why?
|
| Computed Tomography Angiography | 1 | 2021 | 198 | 0.160 |
Why?
|
| Cardiovascular Diseases | 1 | 2012 | 1951 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2021 | 1688 | 0.160 |
Why?
|
| Papillomavirus Infections | 1 | 2023 | 293 | 0.160 |
Why?
|
| Binding, Competitive | 2 | 2012 | 185 | 0.160 |
Why?
|
| Signal-To-Noise Ratio | 1 | 2018 | 41 | 0.150 |
Why?
|
| Placentation | 1 | 2019 | 55 | 0.150 |
Why?
|
| Limit of Detection | 1 | 2018 | 63 | 0.150 |
Why?
|
| Iodine | 2 | 2016 | 23 | 0.150 |
Why?
|
| Solubility | 1 | 2018 | 135 | 0.150 |
Why?
|
| Disease Progression | 2 | 2021 | 2049 | 0.150 |
Why?
|
| Adult | 5 | 2025 | 29512 | 0.150 |
Why?
|
| Child Abuse | 1 | 2021 | 195 | 0.150 |
Why?
|
| Head and Neck Neoplasms | 2 | 2014 | 502 | 0.150 |
Why?
|
| Molecular Conformation | 1 | 2018 | 100 | 0.150 |
Why?
|
| Aortic Aneurysm | 1 | 2021 | 235 | 0.150 |
Why?
|
| Brain Diseases | 1 | 2021 | 299 | 0.140 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2014 | 668 | 0.140 |
Why?
|
| Chickens | 1 | 2017 | 637 | 0.140 |
Why?
|
| Membranes, Artificial | 1 | 2017 | 27 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2021 | 1394 | 0.140 |
Why?
|
| Chitosan | 1 | 2017 | 20 | 0.140 |
Why?
|
| Models, Animal | 1 | 2019 | 459 | 0.130 |
Why?
|
| Molecular Structure | 2 | 2021 | 291 | 0.130 |
Why?
|
| Doxorubicin | 3 | 2009 | 289 | 0.130 |
Why?
|
| Materials Testing | 1 | 2017 | 73 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2022 | 358 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2022 | 372 | 0.130 |
Why?
|
| Gadolinium DTPA | 2 | 2007 | 47 | 0.130 |
Why?
|
| Cattle | 1 | 2017 | 564 | 0.130 |
Why?
|
| Infant | 4 | 2021 | 12473 | 0.130 |
Why?
|
| Echo-Planar Imaging | 1 | 2016 | 21 | 0.130 |
Why?
|
| Hydrogels | 1 | 2017 | 82 | 0.130 |
Why?
|
| Heterografts | 1 | 2016 | 171 | 0.130 |
Why?
|
| Pericardium | 1 | 2017 | 81 | 0.130 |
Why?
|
| Rabbits | 3 | 2007 | 710 | 0.130 |
Why?
|
| Child, Preschool | 4 | 2021 | 14016 | 0.130 |
Why?
|
| Sensitivity and Specificity | 5 | 2015 | 2050 | 0.130 |
Why?
|
| Multimodal Imaging | 1 | 2016 | 112 | 0.130 |
Why?
|
| Magnetic Resonance Angiography | 2 | 2007 | 163 | 0.120 |
Why?
|
| In Vitro Techniques | 1 | 2017 | 968 | 0.120 |
Why?
|
| Time Factors | 6 | 2022 | 6311 | 0.120 |
Why?
|
| Organometallic Compounds | 2 | 2016 | 107 | 0.120 |
Why?
|
| Gated Blood-Pool Imaging | 1 | 2015 | 3 | 0.120 |
Why?
|
| Life Expectancy | 1 | 2015 | 53 | 0.120 |
Why?
|
| Retinal Dehydrogenase | 1 | 2014 | 10 | 0.120 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2015 | 80 | 0.120 |
Why?
|
| Gestational Age | 1 | 2019 | 1157 | 0.120 |
Why?
|
| Radiation Dosage | 1 | 2015 | 135 | 0.120 |
Why?
|
| Biomarkers | 2 | 2022 | 3066 | 0.110 |
Why?
|
| Models, Molecular | 1 | 2018 | 1068 | 0.110 |
Why?
|
| Whole Body Imaging | 2 | 2012 | 29 | 0.110 |
Why?
|
| Fanconi Anemia | 1 | 2014 | 44 | 0.110 |
Why?
|
| Drug Compounding | 2 | 2011 | 36 | 0.110 |
Why?
|
| Isoenzymes | 1 | 2014 | 229 | 0.110 |
Why?
|
| Molecular Imaging | 2 | 2016 | 61 | 0.110 |
Why?
|
| Retrospective Studies | 8 | 2023 | 16331 | 0.110 |
Why?
|
| Drug Design | 2 | 2021 | 147 | 0.110 |
Why?
|
| Models, Economic | 1 | 2013 | 51 | 0.110 |
Why?
|
| Equipment Failure Analysis | 1 | 2013 | 85 | 0.110 |
Why?
|
| Immunohistochemistry | 3 | 2012 | 1690 | 0.110 |
Why?
|
| Flow Cytometry | 2 | 2013 | 797 | 0.100 |
Why?
|
| Phosphatidylethanolamines | 1 | 2012 | 21 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 2 | 2016 | 1003 | 0.100 |
Why?
|
| Risk | 1 | 2015 | 755 | 0.100 |
Why?
|
| Chemistry, Pharmaceutical | 3 | 2007 | 47 | 0.100 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 419 | 0.100 |
Why?
|
| Triage | 1 | 2013 | 138 | 0.100 |
Why?
|
| Fetus | 1 | 2016 | 585 | 0.100 |
Why?
|
| Concanavalin A | 1 | 2012 | 16 | 0.100 |
Why?
|
| Apolipoproteins E | 1 | 2013 | 189 | 0.100 |
Why?
|
| Uterus | 1 | 2016 | 569 | 0.100 |
Why?
|
| Administration, Intravenous | 1 | 2012 | 145 | 0.100 |
Why?
|
| Coordination Complexes | 1 | 2011 | 6 | 0.100 |
Why?
|
| Dextrans | 1 | 2012 | 45 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 292 | 0.100 |
Why?
|
| Cell Survival | 2 | 2012 | 807 | 0.090 |
Why?
|
| Sodium Chloride | 1 | 2012 | 94 | 0.090 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2012 | 117 | 0.090 |
Why?
|
| Equipment Design | 1 | 2013 | 596 | 0.090 |
Why?
|
| Myocardium | 1 | 2017 | 997 | 0.090 |
Why?
|
| Microscopy, Fluorescence | 1 | 2013 | 325 | 0.090 |
Why?
|
| Neovascularization, Pathologic | 2 | 2011 | 240 | 0.090 |
Why?
|
| Biological Transport | 1 | 2012 | 354 | 0.090 |
Why?
|
| Aptamers, Nucleotide | 1 | 2011 | 28 | 0.090 |
Why?
|
| Mammography | 2 | 2009 | 114 | 0.090 |
Why?
|
| Immunocompetence | 1 | 2011 | 32 | 0.090 |
Why?
|
| Drug Combinations | 1 | 2012 | 268 | 0.090 |
Why?
|
| Cost-Benefit Analysis | 1 | 2013 | 509 | 0.090 |
Why?
|
| Radiographic Image Enhancement | 1 | 2011 | 41 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 1284 | 0.090 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2011 | 290 | 0.090 |
Why?
|
| Residence Characteristics | 2 | 2023 | 278 | 0.090 |
Why?
|
| Cell Line | 2 | 2013 | 2746 | 0.080 |
Why?
|
| HeLa Cells | 1 | 2012 | 806 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2013 | 759 | 0.080 |
Why?
|
| Pandemics | 3 | 2022 | 1108 | 0.080 |
Why?
|
| Surface Properties | 1 | 2009 | 81 | 0.080 |
Why?
|
| NF-kappa B | 1 | 2012 | 455 | 0.080 |
Why?
|
| Cerebral Cortex | 1 | 2012 | 452 | 0.080 |
Why?
|
| Capillary Permeability | 1 | 2009 | 75 | 0.080 |
Why?
|
| Macrophages | 1 | 2013 | 619 | 0.080 |
Why?
|
| Lipids | 1 | 2012 | 514 | 0.080 |
Why?
|
| Comorbidity | 1 | 2013 | 1532 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 1140 | 0.070 |
Why?
|
| Folate Receptors, GPI-Anchored | 2 | 2005 | 54 | 0.070 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 352 | 0.070 |
Why?
|
| Autophagy | 1 | 2011 | 393 | 0.070 |
Why?
|
| Technology, Pharmaceutical | 1 | 2007 | 20 | 0.070 |
Why?
|
| Capsules | 1 | 2007 | 21 | 0.070 |
Why?
|
| Risk Factors | 1 | 2021 | 10281 | 0.070 |
Why?
|
| Hippocampus | 1 | 2012 | 825 | 0.070 |
Why?
|
| Prevalence | 1 | 2013 | 2447 | 0.070 |
Why?
|
| Metabolic Clearance Rate | 1 | 2007 | 143 | 0.070 |
Why?
|
| Spine | 1 | 2007 | 142 | 0.060 |
Why?
|
| Tissue Plasminogen Activator | 1 | 2007 | 115 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2007 | 203 | 0.060 |
Why?
|
| Urethane | 1 | 2004 | 5 | 0.060 |
Why?
|
| Texas | 1 | 2013 | 3585 | 0.060 |
Why?
|
| Photons | 1 | 2025 | 48 | 0.060 |
Why?
|
| Pulmonary Embolism | 1 | 2007 | 177 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2013 | 3447 | 0.060 |
Why?
|
| Anti-Infective Agents | 1 | 2007 | 264 | 0.060 |
Why?
|
| Respiratory Transport | 1 | 2003 | 2 | 0.050 |
Why?
|
| Bronchography | 1 | 2003 | 4 | 0.050 |
Why?
|
| Drug Stability | 1 | 2003 | 57 | 0.050 |
Why?
|
| Respiratory Physiological Phenomena | 1 | 2003 | 17 | 0.050 |
Why?
|
| Finite Element Analysis | 1 | 2003 | 28 | 0.050 |
Why?
|
| Pulmonary Ventilation | 1 | 2003 | 28 | 0.050 |
Why?
|
| Hospitalization | 2 | 2022 | 1780 | 0.050 |
Why?
|
| Radiography, Abdominal | 1 | 2003 | 47 | 0.050 |
Why?
|
| Patient Acuity | 1 | 2023 | 66 | 0.050 |
Why?
|
| Adolescent | 4 | 2022 | 19320 | 0.050 |
Why?
|
| Cadaver | 1 | 2003 | 129 | 0.050 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 2880 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 299 | 0.050 |
Why?
|
| Blood Glucose | 1 | 2006 | 1137 | 0.050 |
Why?
|
| Protein Aggregates | 1 | 2021 | 28 | 0.050 |
Why?
|
| Fluorescent Dyes | 1 | 2023 | 261 | 0.050 |
Why?
|
| Aged | 2 | 2024 | 19771 | 0.050 |
Why?
|
| Mutation | 1 | 2015 | 5824 | 0.050 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2012 | 158 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2021 | 75 | 0.050 |
Why?
|
| Radiometry | 1 | 2021 | 38 | 0.050 |
Why?
|
| Policy | 1 | 2021 | 35 | 0.050 |
Why?
|
| Potassium | 1 | 2022 | 280 | 0.050 |
Why?
|
| Sodium | 1 | 2022 | 295 | 0.040 |
Why?
|
| Dilatation, Pathologic | 1 | 2021 | 93 | 0.040 |
Why?
|
| Protein Folding | 1 | 2021 | 216 | 0.040 |
Why?
|
| Hospitals, Community | 1 | 2021 | 55 | 0.040 |
Why?
|
| Macaca fascicularis | 1 | 2020 | 87 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2021 | 235 | 0.040 |
Why?
|
| Natural Language Processing | 1 | 2021 | 63 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2021 | 181 | 0.040 |
Why?
|
| Brain Neoplasms | 1 | 2009 | 1211 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2021 | 164 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2014 | 883 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 2020 | 382 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2019 | 89 | 0.040 |
Why?
|
| Blood Volume | 1 | 2019 | 81 | 0.040 |
Why?
|
| Diet, High-Fat | 1 | 2021 | 209 | 0.040 |
Why?
|
| Body Composition | 1 | 2022 | 522 | 0.040 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2022 | 539 | 0.040 |
Why?
|
| Machine Learning | 1 | 2021 | 250 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2022 | 490 | 0.040 |
Why?
|
| Logistic Models | 1 | 2023 | 1811 | 0.040 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 328 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2022 | 848 | 0.040 |
Why?
|
| Middle Aged | 2 | 2014 | 26811 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2021 | 541 | 0.030 |
Why?
|
| Hepatitis B Antibodies | 1 | 1997 | 24 | 0.030 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 1997 | 51 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2021 | 929 | 0.030 |
Why?
|
| Polyesters | 1 | 2017 | 39 | 0.030 |
Why?
|
| Meglumine | 1 | 2016 | 14 | 0.030 |
Why?
|
| Peptide Fragments | 1 | 2020 | 779 | 0.030 |
Why?
|
| Critical Care | 1 | 2022 | 656 | 0.030 |
Why?
|
| Rest | 1 | 2016 | 58 | 0.030 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2016 | 81 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2022 | 1563 | 0.030 |
Why?
|
| United States | 2 | 2021 | 10899 | 0.030 |
Why?
|
| Muscle, Skeletal | 1 | 2022 | 947 | 0.030 |
Why?
|
| Cell Death | 2 | 2008 | 240 | 0.030 |
Why?
|
| Nanog Homeobox Protein | 1 | 2014 | 26 | 0.030 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2014 | 41 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 723 | 0.030 |
Why?
|
| Algorithms | 1 | 2021 | 1620 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2014 | 210 | 0.030 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 290 | 0.020 |
Why?
|
| Cells, Cultured | 2 | 2011 | 3038 | 0.020 |
Why?
|
| Hydrodynamics | 1 | 2011 | 25 | 0.020 |
Why?
|
| Magnetics | 1 | 2011 | 40 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2014 | 543 | 0.020 |
Why?
|
| Amides | 1 | 2011 | 89 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 2011 | 53 | 0.020 |
Why?
|
| Beclin-1 | 1 | 2011 | 26 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 1997 | 1018 | 0.020 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2011 | 432 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 2011 | 94 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2011 | 132 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2011 | 152 | 0.020 |
Why?
|
| Electron Spin Resonance Spectroscopy | 1 | 2009 | 22 | 0.020 |
Why?
|
| X-Rays | 1 | 2009 | 27 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2009 | 63 | 0.020 |
Why?
|
| Proteins | 1 | 2014 | 1036 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2011 | 204 | 0.020 |
Why?
|
| Phospholipids | 1 | 2009 | 105 | 0.020 |
Why?
|
| Monte Carlo Method | 1 | 2009 | 95 | 0.020 |
Why?
|
| Carcinoma | 1 | 2011 | 286 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 669 | 0.020 |
Why?
|
| Mammary Neoplasms, Animal | 1 | 2009 | 139 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2011 | 862 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2012 | 723 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2007 | 32 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2011 | 521 | 0.020 |
Why?
|
| Extravasation of Diagnostic and Therapeutic Materials | 1 | 2007 | 8 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 778 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 1883 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2014 | 1893 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2009 | 409 | 0.020 |
Why?
|
| Spinal Nerve Roots | 1 | 2007 | 26 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2009 | 1017 | 0.020 |
Why?
|
| Blood | 1 | 2007 | 104 | 0.020 |
Why?
|
| KB Cells | 1 | 2006 | 5 | 0.020 |
Why?
|
| Diffusion of Innovation | 1 | 2007 | 96 | 0.020 |
Why?
|
| Veins | 1 | 2007 | 107 | 0.020 |
Why?
|
| Rats, Inbred F344 | 1 | 2006 | 105 | 0.020 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2006 | 42 | 0.020 |
Why?
|
| Vena Cava, Inferior | 1 | 2007 | 103 | 0.020 |
Why?
|
| Artifacts | 1 | 2007 | 109 | 0.020 |
Why?
|
| Arteries | 1 | 2007 | 221 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2008 | 1498 | 0.010 |
Why?
|
| Glioma | 1 | 2009 | 491 | 0.010 |
Why?
|
| Apoptosis | 1 | 2011 | 1790 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2011 | 2286 | 0.010 |
Why?
|
| Chick Embryo | 1 | 2003 | 131 | 0.010 |
Why?
|
| Pulmonary Artery | 1 | 2007 | 442 | 0.010 |
Why?
|
| Computational Biology | 1 | 2007 | 810 | 0.010 |
Why?
|
| Phenotype | 1 | 2011 | 4254 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2016 | 12368 | 0.010 |
Why?
|
| Prognosis | 1 | 2008 | 4622 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 2512 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2009 | 4490 | 0.010 |
Why?
|
| Culture Media | 1 | 1997 | 182 | 0.010 |
Why?
|
| Immunoglobulin M | 1 | 1997 | 212 | 0.010 |
Why?
|
| Perfusion | 1 | 1997 | 203 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1997 | 822 | 0.010 |
Why?
|